SU1678369A1 - Method to raise survival of test animals infected with rabies virus - Google Patents
Method to raise survival of test animals infected with rabies virus Download PDFInfo
- Publication number
- SU1678369A1 SU1678369A1 SU894706396A SU4706396A SU1678369A1 SU 1678369 A1 SU1678369 A1 SU 1678369A1 SU 894706396 A SU894706396 A SU 894706396A SU 4706396 A SU4706396 A SU 4706396A SU 1678369 A1 SU1678369 A1 SU 1678369A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- rabies virus
- reserpine
- survival
- infection
- treatment
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 14
- 241000711798 Rabies lyssavirus Species 0.000 title claims abstract description 13
- 230000004083 survival effect Effects 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 title claims abstract description 8
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 claims abstract description 16
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 claims abstract description 16
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 claims abstract description 16
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 claims abstract description 16
- 229960003147 reserpine Drugs 0.000 claims abstract description 16
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000010171 animal model Methods 0.000 claims abstract description 6
- 230000005764 inhibitory process Effects 0.000 claims abstract description 4
- 241000700605 Viruses Species 0.000 claims abstract 2
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 241000699670 Mus sp. Species 0.000 abstract description 7
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 abstract description 4
- 230000000069 prophylactic effect Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 description 6
- QMOWPJIFTHVQMB-UHFFFAOYSA-N benzobarbital Chemical compound O=C1C(CC)(C=2C=CC=CC=2)C(=O)NC(=O)N1C(=O)C1=CC=CC=C1 QMOWPJIFTHVQMB-UHFFFAOYSA-N 0.000 description 5
- 238000010835 comparative analysis Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относитс к вирусологии Цель изобретени - повышение эффективности ингибировани вируса вещества. Дл этого лабораторным животным (кроликам, белым мышам), инфицированным вирусом бешенства, ввод т резерпин парантерально или перорально в дозе 50 мг/кг четырехкратно по лечебной или по лечебно-профилактической схемам. Способ приводит к повышению выживаемости животных. 1 табл.The invention relates to virology. The purpose of the invention is to increase the efficiency of inhibition of the virus substance. For this, laboratory animals (rabbits, white mice) infected with the rabies virus are administered reserpine parenterally or orally at a dose of 50 mg / kg four times according to therapeutic or prophylactic regimens. The method leads to increased survival of animals. 1 tab.
Description
сл Сsl C
Изобретение относитс к вирусологии, Цель изобретени - повышение эффективности ингибировани вируса бешенства.The invention relates to Virology. The purpose of the invention is to increase the effectiveness of inhibition of the rabies virus.
Способ осуществл етс следующим образом .The method is carried out as follows.
Резерпин ввод т лабораторным животным (кроликам, белым мышам) при наличии инфицировани вирусом бешенства по лечебной схеме или по лечебно-профилактической схеме. По лечебной схеме резерпин ввод т животным внутримышечно подкожно или перорально (через зонд) в дозе 50 мкг/кг через 20 - 30 мин после инфицировани , а также один раз в сутки в течение 2 - 4 суток. По лечебно-профилактической схеме резерпин ввод т в дозе 50 мкг/кг подкожно однократно за сутки до инфицировани , однократно в день инфицировани , а также в течение двух суток после инфицировани (1 раз в сутки).Reserpine is administered to laboratory animals (rabbits, white mice) in the presence of a rabies virus infection according to a treatment regimen or a treatment-and-prophylactic regimen. According to the treatment regimen, reserpine is administered to animals intramuscularly subcutaneously or orally (through a probe) at a dose of 50 µg / kg 20 to 30 minutes after infection, and also once a day for 2 to 4 days. According to the treatment-and-prophylactic regimen, reserpine is administered subcutaneously at a dose of 50 µg / kg once a day before infection, once a day of infection, and also within two days after infection (1 time per day).
П р и м е р 1. 10 белых мышей массой 6 - 7 г инфицировали 10 ЛДзо вируса бешенства fixe (штамм Москва). Резерпин вводили по лечебной схеме, начина с инъекциии препарата через 20.- 30 мин после инфицировани . Вводили резерпин подкожно, из расчета 50 мкг/кг один раз в сутки. Лечение продолжалось 4 сут. Выживаемость инфицированных животных составила 70%.PRI me R 1. 10 white mice weighing 6–7 g infected 10 LDOs of the fixe rabies virus (strain Moscow). Reserpine was administered according to the treatment regimen, starting with the injection of the drug 20-30 minutes after the infection. Reserpine was injected subcutaneously, at a rate of 50 µg / kg once a day. The treatment lasted 4 days. The survival rate of infected animals was 70%.
Пример 2. 10 белым мышам резерпин вводили по лечебно-профилактической схеме . Дл этого резерпин вводили подкожно в дозе 50 мкг/кг за сутки до инфицировани . Через 24 ч белых мышей заражали 10 ЛДю фиксированного вируса бешенства. В тот же день им ввели 50 мкг/кг резерпина на физрастворе , затем препарат вводили еще дважды в течение двух суток (один раз вExample 2. 10 white mice reserpine was injected on the treatment-and-prophylactic scheme. For this, reserpine was administered subcutaneously at a dose of 50 µg / kg one day prior to infection. After 24 h, white mice were infected with 10 LD of a fixed rabies virus. On the same day, they were injected with 50 µg / kg of reserpine on saline solution, then the drug was injected twice more over two days (once a day).
соwith
со сь юso you
сутки). Выживаемость животных составила 90%.day). Animal survival was 90%.
Пример. Кроликам, зараженным 10%- ной суспензией мозга белых мышей, погибших от уличного вируса бешенства (штамм Лисий) резерпин вводили как по лечебно- профилактической, так и по лечебной схемам , как внутримышечно, так и перорально (через зонд) в дозе 50 мкг/кг. Все кролики выжили после заражени уличным вирусом бешенства.Example. Rabbits infected with a 10% suspension of the brain of white mice who died from a street rabies virus (Lysii strain) reserpine were administered both according to treatment-and-prophylactic and treatment regimens, both intramuscularly and orally (through a probe) at a dose of 50 μg / kg All rabbits survived infection with street rabies virus.
Преимущество предлагаемого способа перед известным при использовании бензо- нала заключаетс в большей эффективности ингибировани вируса бешенства, что по- вышает выживаемость лабораторных животных в услови х их инфицировани . Кроме того, резерпин обладает высоким защитным действием в отношении вируса бешенства при пероральном применении, в то врем как у бензонала така активность не отмечена.The advantage of the proposed method over the known use of benzonal is the greater effectiveness of the inhibition of the rabies virus, which increases the survival of laboratory animals under the conditions of their infection. In addition, reserpine has a high protective effect against oral rabies virus, while benzonal has no such activity.
В таблице представлен сравнительный анализ выживаемости белых мышей при их лечении предлагаемым способом и известным в услови х экспериментального заражени фиксированным вирусом бешенства (ЮЛДбо).The table presents a comparative analysis of the survival of white mice during their treatment by the proposed method and known under conditions of experimental infection with a fixed rabies virus (LUL).
Как видно из таблицы, при введении резерпина лабораторным животным, зараженным фиксированным вирусом бешенства , их выживаемость повышаетс на 70%As can be seen from the table, with the introduction of reserpine laboratory animals infected with a fixed rabies virus, their survival increases by 70%
лаыйbark
стst
Опыт (жи- Лечебна вотные получали препарат ) Контроль ОпытExperience (curative animals received the drug) Control Experience
Контроль Опыт Контроль ОпытControl Experience Control Experience
КонтрольControl
Лечебно- профилактическа Therapeutic and prophylactic
Лечебна Therapeutic
Лечебно-профилактическа Therapeutic and prophylactic
(р 0,01) при лечебной схеме введени препарата по сравнению с нелинейными животными (контроль) и на 40% (р 0,05) по сравнению с известным, т.е. при введении(p 0.01) with the treatment regimen of drug administration compared with nonlinear animals (control) and 40% (p 0.05) compared with the known, i.e. with the introduction
бензонала по той же лечебной схеме. В случае введени резерпина зараженным животным по лечебно-профилактической схеме их выживаемость повышалась на 80% (р 0,01) по сравнению с контролем и на 30% (рbenzonal by the same treatment regimen. In the case of the administration of reserpine to infected animals according to the treatment-and-prophylactic scheme, their survival increased by 80% (p 0.01) as compared with the control and by 30% (p
0,05) по сравнению с известным способом, где вводилс по лечебно-профилактической схеме бензонал. Таким образом, сравнительный анализ .данных таблицы показывает , что резерпин в предлагаемом способе0.05) compared with the known method, where benzonal was introduced according to the treatment-and-prophylactic scheme. Thus, a comparative analysis of the data in the table shows that reserpine in the proposed method
оказалс эффективнее бензонала в известном способе при применении его как по лечебной, так и по лечебно-профилактической схемам.turned out to be more effective than benzonal in a known way when used in both therapeutic and therapeutic schemes.
Практическое применение резерпина вPractical application of reserpine in
качестве ингибитора вируса бешенства может найти применив в вирусологических лаборатори х страны с целью сохранени поголовь лабораторных животных.As an inhibitor of rabies virus, it can be found in the country’s virological laboratories in order to preserve the livestock of laboratory animals.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU894706396A SU1678369A1 (en) | 1989-06-19 | 1989-06-19 | Method to raise survival of test animals infected with rabies virus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU894706396A SU1678369A1 (en) | 1989-06-19 | 1989-06-19 | Method to raise survival of test animals infected with rabies virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1678369A1 true SU1678369A1 (en) | 1991-09-23 |
Family
ID=21454746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU894706396A SU1678369A1 (en) | 1989-06-19 | 1989-06-19 | Method to raise survival of test animals infected with rabies virus |
Country Status (1)
| Country | Link |
|---|---|
| SU (1) | SU1678369A1 (en) |
-
1989
- 1989-06-19 SU SU894706396A patent/SU1678369A1/en active
Non-Patent Citations (1)
| Title |
|---|
| Авторское свидетельство СССР N51559479, кл. А 61 К 31/00, 01.09.88. * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1161362A (en) | Pharmaceutical compositions containing a corticosteroid substance | |
| ATE157257T1 (en) | ENHANCEMENT OF SUPPRESSIVE REGULATION OF AUTOIMMUNE DISEASES BY ORAL OR ENTERAL ADMINISTRATION OF AUTOANTIGENS | |
| Hirsch et al. | Effects of anti-thymocyte serum on Rauscher virus infection of mice | |
| MD1688G2 (en) | Benzothiophene, benzofuran and indolthiazepinones, oxazepinones and diazepinones, a pharmaceutical composition, a method for inhibiting leukocyte adhesion to endothelial cells for treating inflammatory processes and a method for treating mammals infected with HIV infection. | |
| Worthington et al. | Late therapy with an interferon stimulator in an arbovirus encephalitis in mice | |
| KR940702726A (en) | Use of substituted quinoline-3-carboxyamide compounds and methods of treating multiple sclerosis using the same | |
| SU1678369A1 (en) | Method to raise survival of test animals infected with rabies virus | |
| Stringfellow et al. | Interferon inducers in therapy of infection with encephalomyocarditis virus in mice. I. Effect of single doses of polyriboinosinic-polyribocytidylic acid and tilorone hydrochloride on viral pathogenesis | |
| ES2105923A1 (en) | Compositions containing 5-iodouracil derivatives for the treatment of hepatitis B infections. | |
| KR900001697A (en) | Therapeutic compounds | |
| KR900701278A (en) | Bile acids for the treatment of viral infections | |
| RU2129867C1 (en) | Agent for prophylaxis and treatment of infectious sicknesses and correction of pathological states of live organism | |
| RU1821204C (en) | Anti-influenza drug | |
| AU3874299A (en) | Method for treating cytokine mediated hepatic injury | |
| RU1801002C (en) | Method for treating respiratory diseases in calves | |
| US6380164B1 (en) | Method for treating cytokine mediated hepatic injury | |
| ATE24834T1 (en) | USE OF BETA-(1-ADAMANTYL)-ALPHA, ALPHADIMETHYLETHYLAMINE IN THE MANUFACTURE OF A MEDICATION FOR THE TREATMENT OF EXTERNAL OTITIS IN DOGS. | |
| RU2017485C1 (en) | Method for treatment of leptospirosis at cattle | |
| RU2025126C1 (en) | Agent for treatment and prophylaxis of viral tick-borne encephalitis induced in the experiment | |
| RU1827251C (en) | Inhibitor of virus activity with relation to rabies and west nile viruses | |
| SU1465052A1 (en) | Method of prophylaxis and treatment of helminth infestation of animals | |
| RU2150290C1 (en) | Method of treatment of calves with viral gastroenteric disease | |
| RU2111744C1 (en) | Preparation abactan for treatment and prophylaxis of infectious sicknesses in animals | |
| RU1805959C (en) | Method of controlling viral gastroenteric disease in pigs | |
| KR960703924A (en) | Novel Benzothiophene Analogs as Antiviral Agents as Antiviral Agents |